Altimmune, Inc.
Financials
Valuation Metrics
Altimmune, Inc.'s Market Cap is $632M. At end of 2025 it was $363M. Ranked #2704 of 3,121 in US market (top 87%), #1164 of 1,463 on NASDAQ (top 80%), #213 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $632M | US#2,704/3,121 Sec#213/266 |
| Revenue | $31000.00 | US#2,887/3,121 Sec#195/266 |
| Net Income | $-92M | US—/3,121 Sec—/266 |
| Total Assets | $527M | US#2,749/3,121 Sec#159/266 |
| Net Assets | $474M | US#2,264/3,121 Sec#112/266 |
| Employees | 57 | US#2,708/3,121 Sec#209/266 |
| Value | ||
| P/B | 1.33x | US#720/3,121 Sec#27/266 |
| P/S | 15415.64x | US#3,000/3,121 Sec#204/266 |
| FCF Yield | -12.11% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -19.35% | US#2,476/3,121 Sec#97/266 |
| ROA | -17.40% | US#2,767/3,121 Sec#123/266 |
| Op. Margin | -323306.45% | US#2,887/3,121 Sec#195/266 |
| Revenue Growth | 55.00% | US#199/3,121 Sec#46/266 |
| Financial Health | ||
| Debt Ratio | 11.18% | US#124/3,121 Sec#55/266 |
| Total Debt | $36M | US#2,673/3,121 Sec#171/266 |
| FCF | $-77M | US#2,590/3,121 Sec#131/266 |
| Cash | $63M | US#2,475/3,121 Sec#213/266 |
| Current Ratio | 26.78x | US#92/3,121 Sec#13/266 |
| Performance | ||
| 1Y Return | -16.02% | US#2,096/3,121 Sec#201/266 |
| 1M Return | 4.17% | US#273/3,121 Sec#32/266 |
| From 52W High | -49.53% | US#2,719/3,121 Sec#214/266 |
| 1Y MDD | -58.09% | US#2,738/3,121 Sec#210/266 |
| Trading | ||
| Volume | 11,079,020 shares | US#498/3,121 Sec#42/266 |
| Trading Value | $36M | US#2,274/3,121 Sec#186/266 |
| Per Share | ||
| EPS | $-0.47 | US—/3,121 Sec—/266 |
| BPS | $2.44 | US#2,546/3,121 Sec#170/266 |
Company Info
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.